Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short | Global News Avenue

Eli Lilly (Liberal) Most of the reports on Thursday were worse than expected fourth-quarter results, but the drugmaker made better-than-estimated adjusted profits.

Eli Lilly reported net income of $4.41 billion, or $4.88 per share, with revenue of $13.53 billion. Analysts already expect Profit per share was $4.52 billion, or $4.99 per share, and revenue per share was $13.56 billion.

After adjusting the one-time cost, Eli Lilly adjusted it Earnings per share (EPS) $5.32 $5.11 $5.11.

Sales of the company’s blockbuster loss drugs, Mounjaro and Zepbound, rose to $3.53 billion and $1.91 billion, respectively, lower than expected $3.65 billion and $20.4 billion.

Eli Lilly said it expects revenues between $58.0 and $61 billion in 2025, with revenues ranging from $22.05 to $23.55 per share and adjusted earnings per share of $22.50 to $24.00. These ranges are largely in line with or exceed expectations.

The result is a day after competitor Novo Nordisk (NGOs), Denmark (Danish The highest estimate in its fourth quarter report.

Eli Lilly shares immediately rose more than 2% after the report. Over the past 12 months, they have entered about 20% of the day. By comparison, Novo Nordisk stock has fallen about 25% over the past year.